Agios Pharmaceuticals AGIO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's additional paid-in capital?
- Agios Pharmaceuticals (AGIO) reported additional paid-in capital of $2.57B in Q1 2026.
- How has Agios Pharmaceuticals's additional paid-in capital changed year-over-year?
- Agios Pharmaceuticals's additional paid-in capital increased by 2.6% year-over-year, from $2.51B to $2.57B.
- What is the long-term trend for Agios Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's additional paid-in capital has grown at a 2.6% compound annual growth rate (CAGR), from $2.24B to $2.56B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.